Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

History

 
Health care that is driven by quality across a range of services within the hospital system is attractive and marketable to other countries. The image of hospitals as upmarket hotels can be transported but only through the application of consistent, safe and considerate patient care. Establishment of a hospital accreditation system in Lebanon, once fully implemented will pave the way for the provision of good quality of health care. As the accreditation system matures the standards will further develop and quality assurance and quality improvement will lead on to the more precise measurement of health outcomes.

A broad range of quality measures will be discussed in this paper to show that when the ethic of quality is embedded within the health system, the delivery, utilisation and growth of acute hospital services in Lebanon is more attractive to local patients and neighboring countries. It is vital that the concepts of quality assurance and quality improvement be seen as critical and not as an adjunct to hotel services, and quality and accommodation standards are not viewed in isolation. The development of quality hotel services is linked quite clearly to quality generally, whether it is in the building/infrastructural component, the furbishing component, equipment or the patient care services.

Quality assurance principles and hospital accreditation address quality of care deficiencies and harmful and/or wasteful practices, and can stimulate debate between public and private providers, policy makers and consumers on what practices conform to the latest reliable evidence. This promotes a wider dissemination of knowledge. Increased knowledge and awareness by the public ensures that hospitals achieve greater throughputs because of the public's faith that the hospital is able to meet the wide range of quality standards.

Hospital management have often remarked during visits of the OPCV Survey Team that unless a hospital provided "the full options"- that is a complete range of the latest sophisticated medical technology - then it was not considered to be a good hospital. Scant attention is paid to whether the size and complexity of the hospital warrants a complete range of equipment, or indeed whether the hospital can provide the qualified staff necessary to operate such equipment safely. The image of what constitutes a good hospital is generally supported by the current Hospital Classification system and it this image that is required to be changed through the implementation of quality assurance/improvement to support the marketing of Lebanon's hospital services to other countries. A public education campaign is therefore a concomitant exercise to be carried out in parallel with the development of the quality approach .
    3
    ...
ATC Name B/G Ingredients Dosage Form Price
C07AB07 BISOPROLOL REF G Bisoprolol hemifumarate - 2.5mg 2.5mg Tablet, coated, scored 272,800 L.L
C07AB07 BISOPROLOL NORMON G Bisoprolol hemifumarate - 5mg 5mg Tablet, film coated 321,178 L.L
C07AB07 BISOPROLOL REF G Bisoprolol hemifumarate - 5mg 5mg Tablet, coated, scored 272,800 L.L
L01DC01 BLEO-CELL G Bleomycin (sulfate) - 15mg 15mg Injectable powder for solution 3,054,554 L.L
L01DC01 BLEOCIN B Bleomycin (sulfate) - 15U 15U Injectable lyophilised powder for solution 2,109,833 L.L
L01FX07 BLINCYTO BioTech Blinatumomab - 35mcg 35mcg Injectable lyophilised powder for solution+stabilizer 239,484,334 L.L
L01XG01 BORTEZOMIB NEAPOLIS G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder for solution L.L
L01XG01 BORCADE G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder 11,020,381 L.L
L01XG01 BORCADE G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder 11,020,381 L.L
L01XG01 BORTEZOMIB ACCORD G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 13,007,658 L.L
L01XG01 BORTEZOMIB GP PHARM G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 13,007,658 L.L
L01XG01 BORTEZOMIB NEAPOLIS G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder for solution 14,169,600 L.L
L01XG01 BORTEZOMIB SPC G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 15,743,401 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated 49,522,064 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 62.5mg 62.5mg Tablet, film coated 49,522,064 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 62.5mg 62.5mg Tablet, film coated L.L
L01EA04 BOSULIF B Bosutinib - 100mg 100mg Tablet, film coated 35,663,747 L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated 123,564,667 L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated 154,453,246 L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated L.L
S01EA05 BGLAU G Brimonidine tartrate - 0.2% 0.2% Drops solution 638,325 L.L
S01EA05 BRIMO G Brimonidine tartrate - 0.2% 0.2% Drops solution 658,483 L.L
S01EA05 BRIMOGAN G Brimonidine tartrate - 0.2% w/v 0.2% w/v Drops solution 483,783 L.L
S01EA05 BRIMONIDINE BIOGARAN G Brimonidine tartrate - 2mg/ml 0.2% Drops solution 412,560 L.L
N03AX23 BRIVIACT B Brivaracetam - 10mg/ml 10mg/ml Solution 10,314,804 L.L
N03AX23 BRIVIACT B Brivaracetam - 25mg 25mg Tablet, film coated 9,627,931 L.L
N03AX23 BRIVIACT B Brivaracetam - 50mg 50mg Tablet, film coated 9,627,931 L.L
S01LA06 BEOVU BioTech Brolucizumab - 120mg/ml 120mg/ml Injectable solution 68,669,378 L.L
    3
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025